comparemela.com

Latest Breaking News On - Australian stock exchange msb ax - Page 1 : comparemela.com

United States Food & Drug Administration (FDA) Grants

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United statesSteve dabkowskiSilviu itescuPaul hughesDrug administrationCorporate communications investorsAustralian securities exchangeMesoblast the companyDrug designation programMesoblast limited nasdaqJournal of the american college cardiologyUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open

Appendix 4C Quarterly Activity Report for Quarter Ended

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for.

United statesUnited kingdomSteve dabkowskiSilviu itescuPaul hughesMarrow transplant clinical trials networkNational institutes of healthProgram in chronic heart failureAustralian securities exchangeCorporate communications investorsPharmaceuticals coMesoblast limited nasdaqProgram in pediatric congenital heart diseaseChief executive silviu itescuRare pediatric diseaseHost disease

United States Food & Drug Administration (FDA) Grants

FDA GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR® (REXLEMESTROCEL-L) IN CHILDREN WITH CONGENITAL HEART DISEASE.

United statesSilviu itescuSteve dabkowskiPaul hughesMesoblast limited nasdaqDrug administrationJournal of the american college cardiologyCorporate communications investorsAustralian securities exchangeRevascor increases size of left heart chamberMesoblast the companyLeft heart chamberImproves surgical outcomesHypoplastic left heart syndromeResults publishedCardiovascular surgery

Mesoblast Files for Orphan Drug and Pediatric Rare Disease

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United statesSteve dabkowskiPaul hughesMesoblast the companyMesoblast limited nasdaqAustralian securities exchangeJournal of the american college cardiologyCorporate communications investorsDrug administrationUnited states foodCardiovascular surgery openMesoblast limitedPatients with heartAmerican collegePrivate securities litigation reform actAustralian stock exchange msb ax

Mesoblast Partners With Blood and Marrow Transplant

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

New yorkUnited statesGreen bayMedical college of wisconsinPaul hughesSteve dabkowskiSilviu itescuJohn levineNational institutes of healthUnited states national institutes of healthCore transplant centers consortiaBlood instituteUnited states food drug administrationSchool of pharmacyAustralian securities exchangeSteering committee

vimarsana © 2020. All Rights Reserved.